CareDx guides Q4 revenue above estimates
CareDx (NASDAQ:CDNA) expects to incur a loss (GAAP) of around $32M to $34M for the fourth quarter of 2024, on revenue of $85M ...
Zacks.com on MSN5d
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...
Seeking Alpha20d
CareDx: Too Risky For Me
CareDx faces regulatory challenges and lacks a durable competitive advantage in a fragmented and competitive market, with no clear moat to protect its position, leading to a poor risk-reward profile ...
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.
CNN1y
CareDx, Inc.
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products.
Seeking Alpha25d
CareDx: Top Of My Shopping List For 2025
When considering additions to the Compounding Healthcare Investing Group's "Bioreactor" growth portfolio, I find CareDx (NASDAQ:CDNA) to be an intriguing candidate due to their growth potential in ...
Eagle-Tribune1mon
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated ...
CareDx: Balancing Growth Prospects and Risks with a Hold Rating
In a report released today, Yi Chen from H.C. Wainwright reiterated a Hold rating on CareDx (CDNA – Research Report), with a price target of ...